InsidersTradesSigma
Track the RESMED INC share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, RESMED INC has logged 391 reports. Market capitalisation: €35.4bn. The latest transaction was filed on 4 September 2026 (Cession). Among the most active insiders: Farrell Michael J.. Every trade is openly available.
391
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€62m
146 ops.
Sell Volume
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,750 of 29,062 companies
66.9
score / 100
Value50
Quality84
FCF yld4.7%
Earn yld4.0%
EV/EBITDA18.9x
ROE24%
Gross mgn59%
Net mgn27%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations391 total
970 shares@ US$234.730.0006% mcap1.4% of flowResMed Common StockSEC:0000943819-26-000050:0
4,991 shares@ US$205.68950.0032% mcap1.8% of flowResMed Common StockSEC:0000943819-26-000043:1
4,991 shares@ US$146.340.0023% mcap1.3% of flowResMed Common StockSEC:0000943819-26-000043:0
4,991 shares@ US$205.68950.0032% mcap1.8% of flowCommonSEC144:0001959173-26-005734
8,000 shares@ US$225.000.0056% mcap10.9% of flowResMed Common StockSEC:0000943819-26-000040:0
8,000 shares@ US$224.95540.0056% mcap100.0% of flowCommonSEC144:0001628280-26-053728
4,991 shares@ US$146.340.0023% mcap1.6% of flowResMed Common StockSEC:0000943819-26-000038:0
4,991 shares@ US$218.54750.0034% mcap2.3% of flowResMed Common StockSEC:0000943819-26-000038:1
4,991 shares@ US$219.340.0034% mcap2.3% of flowCommonSEC144:0001959173-26-005132
4,991 sharesResMed Common StockSEC:0000943819-26-000035:0
4,991 sharesResMed Common StockSEC:0000943819-26-000035:1
4,991 shares@ US$194.000.0030% mcap1.7% of flowCommonSEC144:0001959173-26-004405
4,991 shares@ US$225.50321.7% of flowResMed Common StockSEC:0000943819-26-000021:1
4,991 shares@ US$146.341.1% of flowResMed Common StockSEC:0000943819-26-000021:0
1,000 shares@ US$224.310.7% of flowResMed Common StockSEC:0000943819-26-000020:0
2,000 shares@ US$225.004.1% of flowResMed Common StockSEC:0000943819-26-000019:0
4,991 shares@ US$146.341.3% of flowResMed Common StockSEC:0000943819-26-000016:0
2,000 shares@ US$260.223.5% of flowResMed Common StockSEC:0000943819-26-000014:0
1,000 shares@ US$254.301.0% of flowResMed Common StockSEC:0000943819-26-000013:0
4,991 shares@ US$146.341.3% of flowResMed Common StockSEC:0000943819-26-000011:0
2,000 shares@ US$251.313.3% of flowResMed Common StockSEC:0000943819-26-000010:0
50 shares@ US$260.001.6% of flowResMed Common StockSEC:0000943819-26-000009:0
1,000 shares@ US$257.031.0% of flowResMed Common StockSEC:0000943819-26-000008:0
2,000 shares@ US$248.833.3% of flowResMed Common StockSEC:0000943819-26-000004:0
4,991 shares@ US$146.341.3% of flowResMed Common StockSEC:0000943819-26-000003:0
25 of 391 declarations
关于 RESMED INC
Resmed Inc.（股票代码 RSMDF）是一家专注于睡眠、呼吸和居家护理的全球健康科技公司。该公司在美国纽约证券交易所上市，股票代码为 RMD，总部位于美国加利福尼亚州圣迭戈。Resmed 由 Peter Farrell 博士于 1989 年在澳大利亚创立，最初围绕用于睡眠呼吸暂停的正压通气疗法构建，此后已发展成为一个涵盖医疗设备、软件和数字患者参与的国际互联健康平台。（[resmed.com](https://www.resmed.com/en-us/about-us/history/?utm_source=openai)） Resmed 的商业模式以诊断、治疗和监测睡眠和呼吸障碍为中心，特别是阻塞性睡眠呼吸暂停和慢性阻塞性肺病。其产品组合包括 CPAP 设备、呼吸机、面罩、配件、云连接监测工具以及供患者、临床医生和家庭护理提供者使用的软件平台。该公司强调一种集成方法，将硬件、数字健康软件和护理管理解决方案相结合，明确专注于将更多护理从医院转移到家庭。（[resmed.com](https://www.resmed.com/en-us/about-us/?utm_source=openai)） 从竞争角度来看，Resmed 是睡眠呼吸暂停治疗和家庭呼吸护理领域的全球领先企业之一。其国际足迹广泛，管理层和公司材料称其业务遍及 140 多个国家，这为公司带来了地理多元化以及对成熟和新兴医疗保健市场的敞口。这种规模很重要，因为 Resmed 的业务受益于对替换面罩、配件、持续患者监测和软件支持的工作流工具的持续需求。（[investor.resmed.com](https://investor.resmed.com/?utm_source=openai)） 主要产品系列包括 AirSense 和 AirCurve 设备、AirFit 和 AirTouch 面罩以及 myAir 等数字解决方案。Resmed 还扩展了其诊断和护理路径能力。2025 年 4 月，它在美国推出了 NightOwl 家庭睡眠呼吸暂停测试，并于 2025 年 5 月收购了 VirtuOx，这是一家专门从事睡眠、呼吸和心脏疾病的独立诊断测试机构。2025 年 12 月，该公司宣布 FDA 批准 Smart Comfort，这是一项人工智能功能，旨在个性化 CPAP 舒适设置，帮助患者开始并坚持治疗。（[investor.resmed.com](https://investor.resmed.com/news-events/press-releases/detail/399/resmed-announces-small-easy-to-use-home-sleep-apnea-test-nightowl-now-available-across-the-us?utm_source=openai)） 最近的财务更新表明其势头强劲。2026 财年第一季度，Resmed 报告收入增长 9% 至 1.34 billion 美元，同时利润率扩大，运营杠杆持续。2025 财年，该公司报告年收入为 5.1 billion 美元，同比增长 10%，这强化了对其睡眠健康和呼吸健康解决方案需求的强劲。对于法语投资者而言，Resmed 提供了医疗保健防御性、经常性收入特征以及日益受到数字健康创新支持的增长概况的组合。（[newsroom.resmed.com](https://newsroom.resmed.com/news-releases/news-details/2025/Resmed-Inc--Announces-Results-for-the-First-Quarter-of-Fiscal-Year-2026/default.aspx?utm_source=openai)）
